Back to Search
Start Over
Single shot tetanus vaccine manufactured by a supercritical fluid encapsulation technology
- Source :
- International Journal of Pharmaceutics. 413:147-154
- Publication Year :
- 2011
- Publisher :
- Elsevier BV, 2011.
-
Abstract
- Single shot vaccines of tetanus toxoid (TT) were manufactured using the NanoMix™ process – a low temperature solvent free encapsulation technology using supercritical fluids. The formulations were injected into mice, and compared to multiple injections of a commercially available alum adsorbed TT vaccine. After 5 months the antibody titres were found to be similar for both the alum adsorbed and microparticle formulations, demonstrating for the first time the potential of formulating antigens in PLA microparticles using the supercritical fluid (NanoMix™) technique to produce single shot vaccines. The results are likely to be due to the maintenance of toxoid bioactivity and some degree of sustained release of the encapsulated antigens, resulting in repeated stimulation of antigen presenting cells eliminating the need for multiple immunisations. This demonstrates the potential of this supercritical fluid processing technique to reduce the need for booster doses in a vaccine regimen.
- Subjects :
- Polymers
Drug Compounding
Polyesters
Pharmaceutical Science
complex mixtures
Drug Administration Schedule
Placebos
Mice
chemistry.chemical_compound
Drug Delivery Systems
Adjuvants, Immunologic
Antigen
Tetanus Toxoid
medicine
Animals
Lactic Acid
Particle Size
Microparticle
Drug Carriers
Mice, Inbred BALB C
Vaccines
Tetanus
Chromatography
Dose-Response Relationship, Drug
Chemistry
Alum
Toxoid
Single shot
medicine.disease
Control Groups
Supercritical fluid
Tetanus vaccine
Delayed-Action Preparations
Immunology
Alum Compounds
Female
Immunization
medicine.drug
Subjects
Details
- ISSN :
- 03785173
- Volume :
- 413
- Database :
- OpenAIRE
- Journal :
- International Journal of Pharmaceutics
- Accession number :
- edsair.doi.dedup.....20a683c11afc4be9725eea07438694f8
- Full Text :
- https://doi.org/10.1016/j.ijpharm.2011.04.053